GoodRx to Match Novo Nordisk Price for Oral Semaglutide

Following the December 2025 approval of 25-mg oral semaglutide (Wegovy; Novo Nordisk), GoodRx has announced availability of the glucagon-like peptide-1 (GLP-1) receptor agonist via its new telemedicine option, GoodRx for Weight Loss.¹ After consulting with a licensed health care provider, self-paying consumers could have access to the 2 lowest doses of the medication, 1.5 mg and 4 mg, for the monthly price of $149 for a limited time.

Through April 15, 2026, monthly supplies of 1.5-mg and 4-mg doses of oral semaglutide will be priced at $149; after that date, the cash price will increase to $199 for the 4-mg dose. For the larger 9-mg and 25-mg oral doses, which will also be available via GoodRx for Weight Loss, the cash price will be $299.

“As new oral GLP-1 options emerge, GoodRx is uniquely positioned to support patients as they navigate their treatment choices,” said Wendy Barnes, president and CEO of GoodRx. “By combining transparent cash pricing with streamlined access to care and broad pharmacy availability, we're helping usher in a simpler, more consumer-friendly chapter in weight management treatment.”

Oral semaglutide for type 2 diabetes (Rybelsus; Novo Nordisk) was first approved in September 2019 based on results seen in the PIONEER clinical trial program,² following the December 2017 approval of a prefilled pen version for weekly use.³ Expanded indications were also given in October 2025 for oral doses of 7 mg and 14 mg to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who are at an elevated risk and for patients without a prior heart attack or stroke.⁴ Findings from the OASIS trial program and the SELECT trial (NCT03574597) supported Novo Nordisk’s application for the newest approval.²

To be eligible to receive oral semaglutide through GoodRx for Weight Loss, potential consumers have to meet with a licensed health care provider, complete an eligibility assessment, and receive a prescription specifically for the Wegovy pill or another FDA-approved GLP-1. Fulfilling these criteria, they will be able to pick up the prescription at one of the more than 70,000 pharmacies across the US that accept the free GoodRx coupons.⁵

The telemedicine service was first introduced in November 2025 and is meant to make GLP-1s more widely available through end-to-end care.⁶ It is a subscription service in which consumers seeking weight management treatment must be enrolled and touts transparent pricing, flexible fulfillment options, and a consumer-first experience among its benefits. The current introductory price is $39 through the end of January, which will increase to $119 on February 1.

At present, the total cost of oral semaglutide can be influenced by factors that include pharmacy choice, insurance coverage status, and whether a patient qualifies for discount or savings programs; the monthly cost for the Rybelsus form of semaglutide ranges from $0 to just over $1400, following additional wholesaler fees that increase the manufacturer list price of $997 for 30 tablets.⁷

Also for weight loss, GoodRx currently offers prefilled pens of semaglutide, sold as Ozempic and Wegovy, for $199 for the first 2 fills of 0.25-mg and 0.50-mg doses—in addition to the $39 per month fee for unlimited online care—and Zepbound (tirzepatide; Eli Lilly) at $299 for the first fill of a 2.5-mg vial and syringe.⁵

References

1. GoodRx now offers Novo Nordisk’s cash price for the launch of the Wegovy pill. News release. GoodRx. January 5, 2026. Accessed January 5, 2026. https://www.businesswire.com/news/home/20260105738223/en/GoodRx-Now-Offers-Novo-Nordisks-Cash-Price-for-the-Launch-of-the-Wegovy-Pill
2. Caffrey M. FDA approves Novo Nordisk's oral semaglutide, first GLP-1 in pill form. AJMC^®. September 20, 2019. Accessed January 5, 2026. https://www.ajmc.com/view/fda-approves-novo-nordisks-oral-semaglutide-first-glp1-in-pill-form
3. Caffrey M. FDA approves semaglutide, Novo Nordisk's once-weekly GLP-1 for type 2 diabetes. AJMC. December 5, 2017. Accessed January 5, 2026. https://www.ajmc.com/view/fda-approves-semaglutide-novo-nordisks-onceweekly-glp1-for-type-2-diabetes
4. Klein H. FDA expands semaglutide label to reduce cardiovascular risk in adults with type 2 diabetes. AJMC. October 20, 2025. Accessed January 5, 2026. https://www.ajmc.com/view/fda-expands-semaglutide-label-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes
5. GoodRx. Accessed January 5, 2026. https://www.goodrx.com/care/services/glp-1-weight-loss
6. GoodRx launches new $39 per month weight loss telemedicine subscription, unveils industry-leading introductory cash price of $199 per month for Ozempic and Wegovy. BusinessWire. News release. November 17, 2025. Accessed January 5, 2025. https://www.businesswire.com/news/home/20251117268209/en/GoodRx-Launches-New-%2439-Per-Month-Weight-Loss-Telemedicine-Subscription-Unveils-Industry-Leading-Introductory-Cash-Price-of-%24199-Per-Month-for-Ozempic-and-Wegovy
7. Willson A. Ro. How much does oral semaglutide cost with and without insurance? December 9, 2025. Accessed January 5, 2026. https://ro.co/weight-loss/oral-semaglutide-cost/